Resverlogix Corp. (“Resverlogix”) (TSX:RVX) today announced the publication of an article entitled “ Reduction in the Risk of Major Adverse Cardiovascular Events with the BET Protein Inhibitor Apabetalone in Patients with Recent Acute Coronary Syndrome, Type 2 Diabetes, and Moderate to High Likelihood of Non-Alcoholic Fatty Liver Disease ” in the American Journal of Preventive Cardiology.
CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) --Resverlogix Corporation (“Resverlogix”) (TSX:RVX) today announced the publication of an article entitled “Reduction in the Risk of Major Adverse Cardiovascular Events with the BET Protein Inhibitor Apabetalone in Patients with Recent Acute Coronary Syndrome, Type 2 Diabetes, and Moderate to High Likelihood of Non-Alcoholic Fatty Liver Disease” in the American Journal of Preventive Cardiology. The article presents a post-hoc analysis of BETonMACE data, which demonstrates apabetalone treatment improves cardiac outcomes and liver fibrosis scores in patients with moderate-to-high likelihood of advanced liver fibrosis.
The article is published online HERE.
“In this patient group, apabetalone treatment was associated not only with fewer negative cardiovascular outcomes, but also relative improvements in liver fibrosis score,” said Dr. Peter P. Toth, Director of Preventive Cardiology at CGH Medical Center in Sterling, IL, and the corresponding author of the article. “These promising findings make the case for a larger study of non-alcoholic fatty liver disease patients to better understand the scope of apabetalone’s benefit.”
Publication Highlights Include:
- Angulo fibrosis score (FS) has a validated association with non-alcoholic fatty liver disease prevalence
- BETonMACE participants with an elevated FS had higher incidences of major adverse cardiac events (MACE) and hospitalizations due to heart failure (HHF)
- Apabetalone treatment reduced the hazard of HHF (HR=0.53, p=0.01), as well as a composite MACE and HHF (HR=0.76, p=0.03) in BETonMACE participants with elevated FS
- In comparison to the placebo group, patients who received apabetalone treatment saw significantly smaller increases in their liver fibrosis scores
About Apabetalone
Apabetalone (RVX-208), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease progression by regulating the expression of disease-causing genes.
Due to the extensive role for BET proteins in the human body, apabetalone, can simultaneously target multiple disease-related biological processes while maintaining a well-described safety profile – leading to a new way to treat chronic disease. Apabetalone received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) and is the only drug of its class with an established safety record in human clinical trials, with well over 4200 patient-years of safety data across 10 clinical trials.
COVID-19:
Studies – published in prestigious scientific journals (including Cell) – demonstrate that apabetalone has the potential to act against COVID-19 with a unique dual-mechanism: first by preventing viruses from entering the cells and replicating; and second by averting excessive inflammatory reactions that can cause severe and lasting organ damage. The investigational treatment could potentially reduce the severity and duration of COVID-19. Apabetalone’s unique dual-mechanism also means that it has the potential to show efficacy against new COVID-19 variants and may even help fight other viruses.
Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for COVID-19 in Canada and the United States. EVERSANA™ is currently leading clinical outreach and advocacy for apabetalone in the Canadian market.
Cardiology:
Apabetalone is the first therapy of its kind to receive Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) – for a major cardiovascular indication – following the ground-breaking findings from the BETonMACE Phase 3 study. Data from BETonMACE showed apabetalone can potentially prevent major adverse cardiac events among high-risk cardiovascular disease patients who also have type 2 diabetes mellitus.
About Resverlogix
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company and the world leader in epigenetics with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.
Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.
The Company’s clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and COVID-19.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us: Twitter: @Resverlogix_RVX. LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/
Forward Looking Statements:
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with non-alcoholic fatty liver disease, COVID-19, cardiovascular disease and associated comorbidities and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
www.resverlogix.com
